We have studied the role of the RB/p16 tumor suppressor pathway in human cancer focusing primarily on the model of lung cancer. We have established that hypermethylation and gene silencing of p16 occurs in 40% of human non-small cell lung cancers and can be reversed by decitabine therapy. At the Surgery Branch with Dr. Schrump we have begun a clinical trial with decitabine to determine clinical response in lung cancer and to test the ability to hypomethylate specific genetic loci in vivo. We have continued to study alterations within RB gene family members in lung cancer and have characterized several novel mutations in small cell lung cancer. We have also examined novel mutant RB alleles from families with low penetrance of familal retinoblastoma to study the molecular basis for low penetrance of familial retinoblastoma and to define more precisely tumor suppressor activities within the RB product. We have demonstrated that many families with low penetrance carry unstable mutant alleles with temperature-sensitive pocket binding activity which suggest a model for the variable frequency of tumor progression in these patients. We are also analyzing lung tumors that develop in an A/J murine colony that carry RB mutant alleles to determine the effect of RB versus p16 inactivation as the initial genetic hit in this mouse lung cancer model. These mice also develop a high frequency of neuroendocrine tumors and we will study the genetic basis of how RB inactivation facilitates the initiation or progression of these tumors. We had previously isolated a unique member of the Hsp70 chaperone family, called Stch, during a screen for RB binding partners. We have now identified a short peptide within Stch that is conserved in the ATPase domain of Hsp70 members and that binds a family of human ubiquitin-like genes. These findings suggest a broader role for the Hsp70-like ATPase family in regulating cell cycle and cell death events and may offer a direct link between protein chaperone activity and the 26S proteasome. - cell cycle, retinoblastoma, lung cancer, tumor suppressor genes, heat shock proteins, neuroendocrine, - Human Tissues, Fluids, Cells, etc.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC007256-11
Application #
6290789
Study Section
Special Emphasis Panel (M)
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Komiya, T; Coxon, A; Park, Y et al. (2010) Enhanced activity of the CREB co-activator Crtc1 in LKB1 null lung cancer. Oncogene 29:1672-80
Kaye, Frederic J (2009) Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther 8:1399-408
Chen, M; Rahman, L; Voeller, D et al. (2007) Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 26:4817-24
Tirado, Yamilet; Williams, Michelle D; Hanna, Ehab Y et al. (2007) CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer 46:708-15
Thomas, Roman K; Baker, Alissa C; Debiasi, Ralph M et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-51
Kaye, Frederic J (2006) Emerging biology of malignant salivary gland tumors offers new insights into the classification and treatment of mucoepidermoid cancer. Clin Cancer Res 12:3878-81
Komiya, T; Park, Y; Modi, S et al. (2006) Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene 25:6128-32
Chute, John P; Taylor, Elizabeth; Williams, John et al. (2006) A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 12:888-96
Kaye, Frederic J (2005) A curious link between epidermal growth factor receptor amplification and survival: effect of ""allele dilution"" on gefitinib sensitivity? J Natl Cancer Inst 97:621-3
Paez, J Guillermo; Janne, Pasi A; Lee, Jeffrey C et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-500

Showing the most recent 10 out of 12 publications